Cambridge Antibody - Re Directorate
September 14 1998 - 2:35AM
UK Regulatory
RNS No 8821r
CAMBRIDGE ANTIBODY TECHNOLOGY
14th September 1998
BOARD CHANGE
Melbourn, UK: Cambridge Antibody Technology Group plc (CAT) today announces
that one of the Group's five non-executive directors, Dr Stuart Weisbrod, will
resign at the end of the Group's financial year on 30 September 1998.
Dr Weisbrod was appointed as a director of CAT in June 1996. Earlier this
year he co-founded Merlin BioMed Asset Management, a fund management company
which invests globally in the life science industries.
On his resignation, Dr Weisbrod said:
"I have greatly enjoyed the last two and a half years on CAT's Board and
working with CAT's management team. My other commitments mean that I no
longer have sufficient time to devote to CAT's affairs but I leave the Group
in the hands of a strong and able Board of directors and look forward to
watching progress over the years to come."
Professor Peter Garland, Chairman of CAT, commented:
"Whilst we are obviously sad to see Stuart go, we fully understand the reasons
behind his departure and wish him every success with Merlin BioMed. I would
like to take this opportunity to thank him for his support over the last two
and a half years. He has been supportive in all areas of our development and
his advice has been invaluable, particularly over the time of our successful
float last year."
The Board of CAT:
Professor Peter Garland - Non-executive Chairman
Dr David Chiswell - CEO
John Aston - Finance Director
Dr Kevin Johnson - Research Director
Dr David Glover - Medical Director
Dr James Foght - Non-executive Director
Professor Sir Aaron Klug - Non-executive Director
Dr John Stocker - Non-executive Director
Alistair Cumming - Non-executive Director
END
BOAFCDCPODKDACD
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Aug 2023 to Aug 2024